Capital Advantage, Inc. Savara Inc Transaction History

Capital Advantage, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$1.05 - $1.36 $15,390 - $19,934	-14,658 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $22,133 - $33,566	14,658 New	14,658 $25,000
Q1 2021 Apr 26, 2021	SELL	$1.17 - $2.33 $17,149 - $34,153	-14,658 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$2.16 - $3.2 $31,661 - $46,905	14,658 New	14,658 $39,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Capital Advantage, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital Advantage, Inc. with notifications on news.